Conference Proceedings
Tamoxifen and contralateral breast cancer (CBC) risk for BRCA1 and BRCA2 mutation carriers: An updated analysis of data from the Kathleen Cuningham Foundation consortium for research into familial breast cancer, the International BRCA1 and BRCA2 Carrier cohort study and the breast cancer family registry
Kelly-Anne Phillips, Roger L Milne, Julie K Bassett, John L Hopper, Saundra S Buys, Mary B Daly, Maartje J Hooning, Thea M Mooij, Nadine Andrieu, Antonis C Antoniou, Matti A Rookus, Douglas F Easton, Terry Mary-Beth
CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2018
Abstract
Abstract Background: Findings from an analysis published in 2013, using combined retrospective and prospective data pooled from 3 cohort studies, were consistent with tamoxifen use after 1st breast cancer (BC) being associated with reduced CBC risk for both BRCA1 and BRCA2 mutation carriers, although the analysis of prospective data alone (based on 100 incident CBCs) gave inconclusive results. The association did not differ by estrogen receptor (ER) status of the 1st BC, suggesting that tamoxifen may be a useful secondary BC prevention agent for mutation carriers regardless of the ER status of their 1st BC. The aim of this updated analysis was to assess these associations afte..
View full abstract